P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY

Bibliographic Details
Main Authors:	Uwe Platzbecker, Sheida Hayati, Aarif Ahsan, Amit Verma, Srinivas Aluri, Shelonitda Rose, Anita Gandhi, Rajasekhar Nvs Suragani, Sadanand Vodala
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000969676.37904.8e

Similar Items

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
by: Srinivas Aluri, et al.
Published: (2023-08-01)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
by: Matteo Giovanni Della Porta, et al.
Published: (2023-08-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
by: Steven Fishbane, et al.
Published: (2019-09-01)

A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
by: J Wilson, et al.
Published: (2007-04-01)

Comparison Of The Effectiveness And Safety Of Anemia Epoetin Alfa With Epoetin Beta Inhemodialysis Routine Patients At Haji Rsu Surabaya
by: Gunawan Widodo, et al.
Published: (2021-12-01)

The use of epoetin alfa biosimilar in the anemia management in hemodialysis patients
by: I. O. Dudar, et al.
Published: (2021-02-01)

Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients
by: Amel Harzallah, et al.
Published: (2015-01-01)

Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
by: Seyed Ashkan Hosseini, et al.
Published: (2020-06-01)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
by: Francesca Vinchi, et al.
Published: (2024-03-01)

INFLUENCE OF EPOETIN ALFA ON LEVEL OF PROINFLAMMATORY AND ANTIINFLAMMATORY CYTOKINE OF PATIENTS IN MAINTENCE HEMODIALYSIS
by: I. Dudar, et al.
Published: (2014-03-01)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
by: Arrieta J, et al.
Published: (2014-10-01)

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report
by: Behler Caroline M, et al.
Published: (2009-07-01)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
by: E.J.F. Santos, et al.
Published: (2018-05-01)

THE COMPLEX INTENSIVE THERAPY INCLUDING APPLICATION EPOETIN ALFA AT THE SERIOUS СONCOMITANT BRAIN INJURY
by: E. A. Lebedeva, et al.
Published: (2013-03-01)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
by: Bhanu Prasad, et al.
Published: (2020-06-01)

Darbepoetin versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
by: Pilar M Samper Ots, et al.
Published: (2008-01-01)

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
by: Giovanni Rosti, et al.
Published: (2017-01-01)

Highlights on the Luspatercept Treatment in Thalassemia
by: Yesim Aydinok
Published: (2023-02-01)

LUSPATERCEPT – A TREATMENT FOR THALASSEMIA?
by: Taimoor Hassan
Published: (2021-09-01)

Luspatercept in patients with lower-risk myelodysplastic syndromes
by: Fenaux, P, et al.
Published: (2020)

THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY
by: Müzeyyen Aslaner Ak, et al.
Published: (2023-10-01)

LUSPATERCEPT – a better strategy for thalassemia?
by: Mustafa Saleem Patel, et al.
Published: (2021-12-01)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
by: Jay B. Wish, et al.
Published: (2019-09-01)

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach
by: Ly Minh Nguyen, et al.
Published: (2020-10-01)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
by: Nicholas Jackson, et al.
Published: (2020-07-01)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
by: Bicheng Liu, et al.
Published: (2022-06-01)

Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open‐label, parallel‐group, non‐inferiority Phase III trail
by: Nan Chen, et al.
Published: (2022-03-01)

Fatigue visual analogue scale score correlates with quality of life in cancer patients receiving epoetin alfa (Sandoz) for chemotherapy-induced anaemia: The CIROCO study
by: Jerome Desramé, et al.
Published: (2023-01-01)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers
by: Yoon S, et al.
Published: (2017-10-01)

LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA
by: Y. Gong, et al.
Published: (2024-01-01)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
by: Khaled M. Musallam, et al.
Published: (2023-08-01)

Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice
by: Wenbin An, et al.
Published: (2023-12-01)

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
by: M. D. Cappellini, et al.
Published: (2022-06-01)

Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation model.
by: Jörg Tomeczkowski, et al.
Published: (2013-01-01)

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model
by: Louise Crathorne, et al.
Published: (2016-02-01)

Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
by: Derbyshire L, et al.
Published: (2013-11-01)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
by: Filomena Longo, et al.
Published: (2023-03-01)

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
by: Danny Jeyaraju, et al.
Published: (2023-08-01)

Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
by: Junya Tani, et al.
Published: (2020-01-01)